Page last updated: 2024-10-24

camostat and Fibrosis

camostat has been researched along with Fibrosis in 6 studies

camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients.

Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.

Research Excerpts

ExcerptRelevanceReference
"Camostat mesilate (CM), an oral protease inhibitor, has been used clinically for the treatment of chronic pancreatitis in Japan."7.73Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity. ( Arita, Y; Fujimori, N; Gibo, J; Hisano, T; Inoue, M; Ito, T; Kawabe, K; Nawata, H; Oono, T, 2005)
"The results of the present study suggest that camostat greatly inhibits pancreatic inflammation and prevents and reverses fibrosis and atrophy of the pancreas in the genetically obese and CCK-1 receptor-deficient OLETF rats."7.73Preventive and therapeutic effects of the protease inhibitor camostat on pancreatic fibrosis and atrophy in CCK-1 receptor-deficient rats. ( Jia, D; Otsuki, M; Taguchi, M, 2005)
"Camostat has a beneficial effect on pancreatic fibrosis induced by the administration of a SOD inhibitor, which inhibits the proliferation and activation of PSC."7.73Camostat, an oral trypsin inhibitor, reduces pancreatic fibrosis induced by repeated administration of a superoxide dismutase inhibitor in rats. ( Emori, Y; Ichimura, M; Koide, N; Matsumura, N; Mizushima, T; Ochi, K; Shinji, T; Shirahige, A; Tanimoto, M; Tanioka, H, 2005)
"Camostat mesilate (CM), an oral protease inhibitor, has been used clinically for the treatment of chronic pancreatitis in Japan."3.73Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity. ( Arita, Y; Fujimori, N; Gibo, J; Hisano, T; Inoue, M; Ito, T; Kawabe, K; Nawata, H; Oono, T, 2005)
"The results of the present study suggest that camostat greatly inhibits pancreatic inflammation and prevents and reverses fibrosis and atrophy of the pancreas in the genetically obese and CCK-1 receptor-deficient OLETF rats."3.73Preventive and therapeutic effects of the protease inhibitor camostat on pancreatic fibrosis and atrophy in CCK-1 receptor-deficient rats. ( Jia, D; Otsuki, M; Taguchi, M, 2005)
"Camostat has a beneficial effect on pancreatic fibrosis induced by the administration of a SOD inhibitor, which inhibits the proliferation and activation of PSC."3.73Camostat, an oral trypsin inhibitor, reduces pancreatic fibrosis induced by repeated administration of a superoxide dismutase inhibitor in rats. ( Emori, Y; Ichimura, M; Koide, N; Matsumura, N; Mizushima, T; Ochi, K; Shinji, T; Shirahige, A; Tanimoto, M; Tanioka, H, 2005)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (66.67)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ueda, M2
Uchimura, K2
Narita, Y2
Miyasato, Y2
Mizumoto, T2
Morinaga, J2
Hayata, M2
Kakizoe, Y2
Adachi, M2
Miyoshi, T2
Shiraishi, N1
Kadowaki, D2
Sakai, Y2
Mukoyama, M2
Kitamura, K2
Nakagawa, T1
Hirata, S1
Gibo, J1
Ito, T1
Kawabe, K1
Hisano, T1
Inoue, M1
Fujimori, N1
Oono, T1
Arita, Y1
Nawata, H1
Jia, D1
Taguchi, M1
Otsuki, M2
Emori, Y1
Mizushima, T1
Matsumura, N1
Ochi, K1
Tanioka, H1
Shirahige, A1
Ichimura, M1
Shinji, T1
Koide, N1
Tanimoto, M1
Nagashio, Y1

Reviews

1 review available for camostat and Fibrosis

ArticleYear
Action of antiproteases on fibrosis in experimental chronic pancreatitis.
    JOP : Journal of the pancreas, 2007, Jul-09, Volume: 8, Issue:4 Suppl

    Topics: Animals; Disease Models, Animal; Esters; Fibrosis; Gabexate; Guanidines; Pancreatitis, Chronic; Prot

2007

Other Studies

5 other studies available for camostat and Fibrosis

ArticleYear
The serine protease inhibitor camostat mesilate attenuates the progression of chronic kidney disease through its antioxidant effects.
    Nephron, 2015, Volume: 129, Issue:3

    Topics: Animals; Antihypertensive Agents; Antioxidants; Blood Pressure; Creatinine; Disease Progression; Est

2015
Combination therapy with renin-angiotensin-aldosterone system inhibitor telmisartan and serine protease inhibitor camostat mesilate provides further renoprotection in a rat chronic kidney disease model.
    Journal of pharmacological sciences, 2016, Volume: 130, Issue:2

    Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazol

2016
Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity.
    Laboratory investigation; a journal of technical methods and pathology, 2005, Volume: 85, Issue:1

    Topics: Animals; Cell Proliferation; Chemokine CCL2; Disease Models, Animal; Dose-Response Relationship, Dru

2005
Preventive and therapeutic effects of the protease inhibitor camostat on pancreatic fibrosis and atrophy in CCK-1 receptor-deficient rats.
    Pancreas, 2005, Volume: 30, Issue:1

    Topics: Actins; Amylases; Animals; Atrophy; Eating; Esters; Fibrosis; Gabexate; Guanidines; Interleukin-6; L

2005
Camostat, an oral trypsin inhibitor, reduces pancreatic fibrosis induced by repeated administration of a superoxide dismutase inhibitor in rats.
    Journal of gastroenterology and hepatology, 2005, Volume: 20, Issue:6

    Topics: Administration, Oral; Animals; Disease Models, Animal; Ditiocarb; Drug Administration Schedule; Este

2005